RAPID TEST SYSTEM FOR MYCOBACTERIAL SUSCEPTIBILITY

耐多药结核病的控制一直受到 缺乏快速的抗菌药敏感性检测方法。这款SBIR 该计划旨在提供一种快速抗生素的新方法 基于One Cell Systems专有凝胶微球的药敏试验 (GMD)封装技术。在第一阶段，微囊化牛分枝杆菌和 以污垢为模型系统，对生长分析进行评价。 GMD。培养1-4天后，对GMD进行荧光染色 有了金胺，可以使用流式细胞仪对GMD进行自动分析 以量化克隆生长和对抗生素的敏感性。此外， 可以检测到3%的抗药性人群的存在。在……里面 第二阶段，这项研究旨在提高检测灵敏度 1%的抗性，并使用临床样本对该技术进行评估。这些 实验将为商业上可行的、快速的 分枝杆菌生长及药敏试验。又一次出现了 在美国，结核病是一个公共卫生问题，这表明 迫切需要快速检测方法。 建议的商业应用：一种快速评估 分枝杆菌的生长和抗菌药敏感性将得到开发。 这种方法将通过允许更快地 介入药物治疗。这种GMD技术也可以适用于 其他传染病的快速敏感性测定。

The control of multidrug-resistant tuberculosis has been hampered by the lack of rapid methods for antimicrobial susceptibility testing. This SBIR program is designed to provide a novel approach to rapid antibiotic susceptibility testing, based on One Cell Systems proprietary gel microdrp (GMD) encapsulation technology. In Phase I, encapsulation of M. bovis and smegmatis was used as a model system to evaluate analysis of growth in GMDs. After culture for 1-4 days, and fluorescent staining of the GMDs with auramine, automated analysis of GMDs by flow cytometry could be used to quantify clonal growth and susceptibility to antibiotics. Furthermore, the presence of a 3% antibiotic-resistant population could be detected. In Phase II, the research is designed to increase the detection sensitivity to 1% resistance and evaluate this technology using clinical samples. These experiments will form the basis for a commercially viable, rapid mycobacterial growth and susceptibility assay. The re-emergence of tuberculosis as a public health problem in the United States points tot he urgent need for rapid detection methods. PROPOSED COMMERCIAL APPLICATION: A method for the rapid assessment of mycobacterial growth and antimicrobial susceptibility will be developed. Such a method will reduce health care costs by allowing faster interventional drug therapy. This GMD technique can also be adapted for rapid susceptibility determinations for other infectious diseases.